Iowa-based Harrisvaccines has developed a vaccine for the H3N2 variant strain of swine flu and, using the company's patented RNA Particle technology, can produce the vaccine within four weeks without culturing the live virus.
Currently, the company has pending U.S. Department of Agriculture licensure for the technology. “We have the ability to produce a swine vaccine for the H3N2 variant strain and are prepared to work with federal officials to make it available should the situation warrant,” said D.L. Harris, DVM, Ph.D., founder and president of Harrisvaccines. “Our patented RNA Particle platform allows for rapid vaccine response to situations such as we saw in the 2009 pandemic H1N1 virus and today with the H3N2 variant strain that is crossing from pigs to humans.
"Our technology is so advanced that the USDA’s Center for Veterinary Biologics did not have a ‘box’ to put us in. Now that we have complied with all the necessary testing and paperwork, we are still waiting to be regulated and fully bring this technology to the market.”